<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003558</url>
  </required_header>
  <id_info>
    <org_study_id>DUT-KWF-CKVO-9801</org_study_id>
    <secondary_id>CDR0000066622</secondary_id>
    <secondary_id>EU-98023</secondary_id>
    <nct_id>NCT00003558</nct_id>
  </id_info>
  <brief_title>Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin</brief_title>
  <official_title>A Randomized Phase III Trial of Paclitaxel, Carboplatin and Etoposide Vs. 5-Fluorouracil and Folinic Acid in the Treatment of Patients With Adenocarcinoma of Unknown Primary Site</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not&#xD;
      yet known which combination chemotherapy regimen is more effective for cancer of unknown&#xD;
      primary origin.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of&#xD;
      combination chemotherapy in treating patients with cancer of unknown primary origin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the overall survival after treatment with paclitaxel, carboplatin, and etoposide&#xD;
           and after treatment with fluorouracil and leucovorin calcium in patients with&#xD;
           adenocarcinoma of unknown primary.&#xD;
&#xD;
        -  Compare the response rates, progression free survival, toxicity profile, and quality of&#xD;
           life between the two regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified by center and&#xD;
      presence or absence of liver metastases.&#xD;
&#xD;
      Patients are randomly assigned to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on&#xD;
           day 1, and oral etoposide on days 1-10. Treatment is repeated every 3 weeks for up to&#xD;
           four courses.&#xD;
&#xD;
        -  Arm II: Patients receive leucovorin calcium IV over 2 hours followed by fluorouracil IV&#xD;
           over 24 hours weekly for 6 weeks. Treatment is repeated every 7 weeks for up to two&#xD;
           courses.&#xD;
&#xD;
      Patients are followed every 3 months after treatment for 1 year or until death. Quality of&#xD;
      life questionnaires are completed at each follow-up.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 120-140 patients will be accrued for this study within 3&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 1998</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Carcinoma of Unknown Primary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of any differentiation grade&#xD;
&#xD;
               -  Excludes the following &quot;treatable&quot; conditions:&#xD;
&#xD;
                    -  Axillary node involvement&#xD;
&#xD;
                    -  Peritonitis carcinomatosis&#xD;
&#xD;
                    -  Blastic bone metastases and/or elevated PSA&#xD;
&#xD;
                    -  Squamous cell cancer with cervical or inguinal presentation&#xD;
&#xD;
                    -  Poorly differentiated carcinoma&#xD;
&#xD;
                         -  Neuroendocrine tumors OR&#xD;
&#xD;
                         -  Tumors located in the mediastinum, retroperitoneum, or nodes&#xD;
&#xD;
          -  At least one measurable metastatic site&#xD;
&#xD;
          -  No brain or meningeal metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Leukocyte count at least 4,000/mm3&#xD;
&#xD;
          -  Thrombocyte count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.4 mg/dL&#xD;
&#xD;
          -  AST and ALT less than 3 times upper limit of normal&#xD;
&#xD;
          -  No cirrhosis of the liver&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.7 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  At least 3 months since myocardial infarction&#xD;
&#xD;
          -  No congestive heart failure, tachydysrhythmia, or unstable angina pectoris&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other serious illness or medical condition&#xD;
&#xD;
          -  No current or prior malignancy except nonmelanomatous skin cancer or carcinoma in situ&#xD;
             of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy (no greater than 25% of bone marrow)&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. L. Jansen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Ziekenhuis Maastricht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2003</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <keyword>adenocarcinoma of unknown primary</keyword>
  <keyword>newly diagnosed carcinoma of unknown primary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

